![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Celadon Pharmaceuticals Plc | LSE:CEL | London | Ordinary Share | GB00BDQYGP38 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.50 | 2.52% | 61.00 | 57.00 | 65.00 | 61.00 | 59.50 | 59.50 | 12,246 | 14:00:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Investment Advice | 149k | -7.14M | -0.1082 | -5.64 | 39.26M |
RNS Number:5848E Celsis International PLC 28 January 2000 APPOINTMENT OF NEW FINANCE DIRECTOR Celsis International plc, the microbial risk management group, is pleased to announce the appointment of Mr. Tony Rouse as Finance Director and Company Secretary, effective from 31st January 2000. Mr. Tony Rouse is a Chartered Accountant, was previously Finance Director of Lucas Ingredients Limited and later Director of Mergers and Acquisitions for that company, before becoming Finance Director of Pilgrim Food Group. Mr. Mark Harris, who has been finance director and company secretary for the last two years, leaves Celsis at the end of January to join a recently established shipping business in Hong Kong. Prior to joining Celsis Mr Harris had spent ten years living in the Far East, and he and his family have decided to return to Hong Kong. Chris Evans, Chairman of Celsis, commented: "We are grateful to Mark for the significant contribution he has made to the development of Celsis over the last two years. During that time, the business has been restructured and has moved into sustained profitability. The business is now built on solid, profitable foundations and we wish him well in his future career. "I am pleased to announce the appointment of Tony Rouse who arrives at an important stage in the development of the Company. His many years experience in the food industry will be invaluable to us as we seek to expand and develop the business." Enquiries Celsis International plc Chris Evans, Chairman ) Jack Rowell, Chief Executive) +44 (0) 1223 426 008 Brunswick Group Limited James Garthwaite) Juliet Marshall ) +44 (0) 171 404 5959 END BOAILFETLAIDFII
1 Year Celadon Pharmaceuticals Chart |
1 Month Celadon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions